Nanoparticle-based highly sensitive MRI contrast agents with enhanced relaxivity in reductive milieu

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Radiology

Background:

• Current magnetic resonance imaging (MRI) contrast agents lack sensitivity for early disease diagnosis and fail to detect biochemical microenvironments.
• Gadolinium (Gd3+) based agents are widely used but face limitations in sensitivity and specificity.

Purpose of the Study:

• To develop a highly sensitive nanoparticle-based MRI contrast agent with enhanced relaxivity and responsiveness to biochemical changes.
• To create a probe capable of early disease detection through targeted accumulation and contrast enhancement in reductive tumor tissues.

Main Methods:

• Co-assembly of nanoparticles from Gd3+ complexed to heparin-poly(dimethylsiloxane) copolymer and a reduction-sensitive amphiphilic peptide.
• Evaluation of r1 relaxivity under varying conditions and assessment of cellular uptake, toxicity, anticoagulation properties, and shelf stability.

Main Results:

• Achieved high r1 relaxivity of 51.7 ± 1.2 mM−1 s−1 (3T).
• Demonstrated increased MRI contrast under reducing conditions due to peptide release.
• Exhibited low cellular uptake, no apparent cellular toxicity (up to 1 mM Gd3+), absence of anticoagulation, and high shelf stability (>7 months).

Conclusions:

• The developed nanoparticle system is a highly sensitive T1 MRI contrast agent.
• Its responsiveness to reductive environments and favorable safety profile make it a promising tool for early cancer diagnosis.
• Potential for accumulation and contrast enhancement in reductive extracellular tumor tissue offers new diagnostic possibilities.